Loading patent…
AssigneePulmatrix Operating Company, Inc.
InventorsJean C. Sung, Jason M. Perry, Michael Tauber
Estimating the term…
A dry powder containing dry particles that contain a tiotropium salt, one or more amino acids, and acid content, and optionally, sodium chloride, and/or one or more additional therapeutic agents, wherein the molar ratio of acid to amino acid is from about 0.0005 to about 5, or 0.002 to about 1. In one aspect, the dry powder containing dry particles is suitable for administration to the respiratory tract. In one aspect, the dry powder containing dry particles is a respirable dry powder contains respirable dry particles that contain a tiotropium salt, one or more amino acids, acid content, sodium chloride, and optionally one or ore additional therapeutic agents, wherein the tiotropium salt is about 0.01% to about 0.5%, the leucine is about 5% to about 40%, the sodium chloride is about 50% to about 90%, the optional one or more additional therapeutic agents are up to about 30%, and the molar ratio of acid to amino acid is from about 0.002 to about 1, where all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%.
A respirable dry powder, comprising respirable dry particles that comprise a tiotropium salt, one or more amino acids, acid content, sodium chloride, and optionally one or more additional therapeutic agents, wherein the tiotropium salt is about 0.01% to about 0.5%, the amino acid is about 5% to about 40%, the sodium chloride is about 50% to about 90%, the optional one or more additional therapeutic agents are up to about 30%, and the molar ratio of acid to amino acid is from about 0.002 to about 1, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%.
(canceled)
A respirable dry powder, comprising respirable dry particles that comprise a tiotropium salt, one or more amino acids, acid content, sodium chloride, and optionally one or more additional therapeutic agents, wherein the tiotropium salt is about 0.01% to about 0.5%, the amino acid is about 5% to about 40%, the sodium chloride is about 50% to about 90%, the optional one or more additional therapeutic agents are up to about 30%, and the molar ratio of acid to tiotropium is from about 2 to about 1000, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%.
A respirable dry powder, comprising respirable dry particles that comprise a tiotropium salt, one or more amino acids, acid content, sodium chloride, and optionally one or more additional therapeutic agents, wherein the tiotropium salt is about 0.01% to about 0.5%, the amino acid is about 5% to about 40%, the sodium chloride is about 50% to about 90%, the optional one or more additional therapeutic agents are up to about 30%, and the molar ratio of acid to tiotropium is from about 2 to about 1000, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%, and wherein when the respirable dry powder comprising respirable dry particles is sealed in a receptacle and stored for about 12 months at a temperature of about 15° C. to about 30° C., the purity of tiotropium is about 96.0% or greater.
(canceled)
(canceled)
12-15. (canceled)
(canceled)
19-20. (canceled)
23-26. (canceled)
29-33. (canceled)
(canceled)
37-38. (canceled)
41-45. (canceled)
47-111. (canceled)
Dependencies are inferred from the claim text.